{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T17:52:42Z","timestamp":1790445162866,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Korea United Pharmaceutical"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"DOI":"10.1007\/s10557-026-07951-x","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T07:22:06Z","timestamp":1788765726000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and Safety of Fixed-Dose Combination Therapy with Cilostazol and Rosuvastatin in Patients with Symptomatic Lower Extremity Peripheral Artery Disease: A Multicenter Randomized Controlled Trial"],"prefix":"10.1007","author":[{"given":"Adelin Dhivi","family":"Kemalasari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Woo","family":"Suh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In Tae","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung-Jun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chul-Min","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donghoon","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Yong","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheol Woong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osung","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han Young","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong Kwon","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki Hyuk","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jang Yong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Guk","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the KUP-UI022-301 investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,7]]},"reference":[{"issue":"9901","key":"7951_CR1","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/S0140-6736(13)61249-0","volume":"382","author":"FGR Fowkes","year":"2013","unstructured":"Fowkes FGR, Rudan D, Rudan I, Aboyans V, Denenberg JO, McDermott MM, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet. 2013;382(9901):1329\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(13)61249-0.","journal-title":"Lancet"},{"issue":"8","key":"7951_CR2","doi-asserted-by":"publisher","first-page":"e1020","DOI":"10.1016\/S2214-109X(19)30255-4","volume":"7","author":"P Song","year":"2019","unstructured":"Song P, Rudan D, Zhu Y, Fowkes FJI, Rahimi K, Fowkes FGR, et al. Global, regional, and national prevalence and risk factors for peripheral artery disease in 2015: an updated systematic review and analysis. Lancet Glob Health. 2019;7(8):e1020\u201330. https:\/\/doi.org\/10.1016\/S2214-109X(19)30255-4.","journal-title":"Lancet Glob Health"},{"issue":"11","key":"7951_CR3","doi-asserted-by":"publisher","first-page":"e34908","DOI":"10.2196\/34908","volume":"8","author":"GW Ryu","year":"2022","unstructured":"Ryu GW, Park YS, Kim J, Yang YS, Ko YG, Choi M. Incidence and Prevalence of Peripheral Arterial Disease in South Korea: Retrospective Analysis of National Claims Data. JMIR Public Health Surveill. 2022;8(11):e34908. https:\/\/doi.org\/10.2196\/34908.","journal-title":"JMIR Public Health Surveill"},{"issue":"1","key":"7951_CR4","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1186\/S12889-019-7439-0","volume":"19","author":"H Kim","year":"2019","unstructured":"Kim H, Kim S, Han S, Rane PP, Fox KM, Qian Y, et al. Prevalence and incidence of atherosclerotic cardiovascular disease and its risk factors in Korea: a nationwide population-based study. BMC Public Health. 2019;19(1):1112. https:\/\/doi.org\/10.1186\/S12889-019-7439-0.","journal-title":"BMC Public Health"},{"key":"7951_CR5","doi-asserted-by":"publisher","unstructured":"Gornik HL, Aronow HD, Goodney PP, Arya S, Brewster LP, Byrd L et al. ACC\/AHA\/AACVPR\/APMA\/ABC\/SCAI\/SVM\/SVN\/SVS\/SIR\/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. Lippincott Williams and Wilkins. 2024. pp. e1313\u2013410. https:\/\/doi.org\/10.1161\/CIR.0000000000001251","DOI":"10.1161\/CIR.0000000000001251"},{"key":"7951_CR6","doi-asserted-by":"publisher","unstructured":"Nordanstig J, Behrendt CA, Baumgartner I, Belch J, B\u00e4ck M, Fitridge R, et al. editors. \u2019s Choice -- European Society for Vascular Surgery (ESVS) 2024 Clinical Practice Guidelines on the Management of Asymptomatic Lower Limb Peripheral Arterial Disease and Intermittent Claudication. Eur J Vasc Endovasc Surg. 2024;67(1):9\u201396. https:\/\/doi.org\/10.1016\/J.EJVS.2023.08.067","DOI":"10.1016\/J.EJVS.2023.08.067"},{"issue":"5","key":"7951_CR7","doi-asserted-by":"publisher","first-page":"2593","DOI":"10.3390\/ijms25052593","volume":"25","author":"M Sohn","year":"2024","unstructured":"Sohn M, Lim S. The Role of Cilostazol, a Phosphodiesterase-3 Inhibitor, in the Development of Atherosclerosis and Vascular Biology: A Review with Meta-Analysis. Int J Mol Sci. 2024;25(5):2593. https:\/\/doi.org\/10.3390\/ijms25052593.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"7951_CR8","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1161\/CIRCRESAHA.116.303566","volume":"116","author":"WR Hiatt","year":"2015","unstructured":"Hiatt WR, Armstrong EJ, Larson CJ, Brass EP. Pathogenesis of the Limb Manifestations and Exercise Limitations in Peripheral Artery Disease. Circ Res. 2015;116(9):1527\u201339. https:\/\/doi.org\/10.1161\/CIRCRESAHA.116.303566.","journal-title":"Circ Res"},{"key":"7951_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003748.PUB4","author":"R Bedenis","year":"2014","unstructured":"Bedenis R, Stewart M, Cleanthis M, Robless P, Mikhailidis DP, Stansby G. Cilostazol for intermittent claudication. Cochrane Database Syst Rev. 2014. https:\/\/doi.org\/10.1002\/14651858.CD003748.PUB4.","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"7951_CR10","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1002\/BJS.8895","volume":"99","author":"JW Stevens","year":"2012","unstructured":"Stevens JW, Simpson E, Harnan S, Squires H, Meng Y, Thomas S, et al. Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication. Br J Surg. 2012;99(12):1630\u20138. https:\/\/doi.org\/10.1002\/BJS.8895.","journal-title":"Br J Surg"},{"issue":"7","key":"7951_CR11","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/S0002-9343(00)00569-6","volume":"109","author":"DL Dawson","year":"2000","unstructured":"Dawson DL, Cutler BS, Hiatt WR, Hobson RW, Martin JD, Bortey EB, et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med. 2000;109(7):523\u201330. https:\/\/doi.org\/10.1016\/S0002-9343(00)00569-6.","journal-title":"Am J Med"},{"issue":"8","key":"7951_CR12","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/J.AMJMED.2006.08.033","volume":"120","author":"S Bangalore","year":"2007","unstructured":"Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med. 2007;120(8):713\u20139. https:\/\/doi.org\/10.1016\/J.AMJMED.2006.08.033.","journal-title":"Am J Med"},{"issue":"4","key":"7951_CR13","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1038\/S41591-024-02896-W","volume":"30","author":"A Agarwal","year":"2024","unstructured":"Agarwal A, Mehta PM, Jacobson T, Shah NS, Ye J, Zhu JJ, et al. Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular disease. Nat Med. 2024;30(4):1199. https:\/\/doi.org\/10.1038\/S41591-024-02896-W.","journal-title":"Nat Med"},{"issue":"9","key":"7951_CR14","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1001\/JAMA.2013.277064","volume":"310","author":"S Thom","year":"2013","unstructured":"Thom S, Poulter N, Field J, Patel A, Prabhakaran D, Stanton A, et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. JAMA. 2013;310(9):918\u201329. https:\/\/doi.org\/10.1001\/JAMA.2013.277064.","journal-title":"JAMA"},{"issue":"4","key":"7951_CR15","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1177\/1358863X12445104","volume":"17","author":"JH Lee","year":"2012","unstructured":"Lee JH, Cho KI, Spertus J, Kim SM. Cross-cultural adaptation and validation of the Peripheral Artery Questionnaire: Korean version for patients with peripheral vascular diseases. Vasc Med. 2012;17(4):215\u201322. https:\/\/doi.org\/10.1177\/1358863X12445104.","journal-title":"Vasc Med"},{"issue":"2","key":"7951_CR16","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.ahj.2003.08.001","volume":"147","author":"J Spertus","year":"2004","unstructured":"Spertus J, Jones P, Poler S, Rocha-Singh K. The Peripheral Artery Questionnaire: A new disease-specific health status measure for patients with peripheral arterial disease. Am Heart J. 2004;147(2):301\u20138. https:\/\/doi.org\/10.1016\/j.ahj.2003.08.001.","journal-title":"Am Heart J"},{"issue":"5","key":"7951_CR17","doi-asserted-by":"publisher","first-page":"e007232","DOI":"10.1161\/CIRCOUTCOMES.120.007232","volume":"14","author":"PA Peri-Okonny","year":"2021","unstructured":"Peri-Okonny PA, Wang J, Gosch KL, Patel MR, Shishehbor MH, Safley DL, et al. Establishing thresholds for minimal clinically important differences for the Peripheral Artery Disease Questionnaire. Circ Cardiovasc Qual Outcomes. 2021;14(5):e007232. https:\/\/doi.org\/10.1161\/CIRCOUTCOMES.120.007232.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"4","key":"7951_CR18","doi-asserted-by":"publisher","first-page":"e022232","DOI":"10.1161\/JAHA.121.022232","volume":"11","author":"AT Tran","year":"2022","unstructured":"Tran AT, Spertus JA, Mena-Hurtado CI, Jones PG, Aronow HD, Safley DM, et al. Association of disease-specific health status with long-term survival in peripheral artery disease. J Am Heart Assoc. 2022;11(4):e022232. https:\/\/doi.org\/10.1161\/JAHA.121.022232.","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"7951_CR19","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1161\/CIRCULATIONAHA.111.075770","volume":"125","author":"TP Murphy","year":"2012","unstructured":"Murphy TP, Cutlip DE, Regensteiner JG, Mohler ER, Cohen DJ, Reynolds MR, et al. Supervised exercise versus primary stenting for claudication resulting from aortoiliac peripheral artery disease: six-month outcomes from the claudication: exercise versus endoluminal revascularization (CLEVER) study. Circulation. 2012;125(1):130\u20139. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.111.075770.","journal-title":"Circulation"},{"issue":"10","key":"7951_CR20","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1016\/J.JVIR.2013.05.057","volume":"24","author":"TP Murphy","year":"2013","unstructured":"Murphy TP, Reynolds MR, Cohen DJ, Regensteiner JG, Massaro JM, Cutlip DE, et al. Correlation of patient-reported symptom outcomes and treadmill test outcomes after treatment for aortoiliac claudication. J Vasc Interv Radiol. 2013;24(10):1427\u201335. https:\/\/doi.org\/10.1016\/J.JVIR.2013.05.057.","journal-title":"J Vasc Interv Radiol"},{"key":"7951_CR21","doi-asserted-by":"publisher","unstructured":"Brown T, Forster RB, Cleanthis M, Mikhailidis DP, Stansby G, Stewart M. Cilostazol for intermittent claudication. Cochrane Database Syst Rev. 2021(6). https:\/\/doi.org\/10.1002\/14651858.CD003748.pub5.","DOI":"10.1002\/14651858.CD003748.pub5"},{"issue":"12","key":"7951_CR22","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.1161\/01.ATV.18.12.1942","volume":"18","author":"MB Elam","year":"1998","unstructured":"Elam MB, Heckman J, Crouse JR, Hunninghake DB, Herd JA, Davidson M, et al. Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arterioscler Thromb Vasc Biol. 1998;18(12):1942\u20137. https:\/\/doi.org\/10.1161\/01.ATV.18.12.1942.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"5","key":"7951_CR23","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/S10557-007-6036-0","volume":"21","author":"S Manickavasagam","year":"2007","unstructured":"Manickavasagam S, Ye Y, Lin Y, Perez-Polo RJ, Huang MH, Lui CY, et al. The cardioprotective effect of a statin and cilostazol combination: relationship to Akt and endothelial nitric oxide synthase activation. Cardiovasc Drugs Ther. 2007;21(5):321\u201330. https:\/\/doi.org\/10.1007\/S10557-007-6036-0.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"4","key":"7951_CR24","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1007\/s00210-023-02758-1","volume":"397","author":"A Hamdy","year":"2024","unstructured":"Hamdy A, El-Bassossy HM, Elshazly SM, El-Sayed SS. Rosuvastatin, but not atorvastatin, enhances the antihypertensive effect of cilostazol in an acute model of hypertension. Naunyn Schmiedebergs Arch Pharmacol. 2024;397(4):2321\u201334. https:\/\/doi.org\/10.1007\/s00210-023-02758-1.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"4","key":"7951_CR25","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1177\/1708538116682911","volume":"25","author":"AM Lazaris","year":"2017","unstructured":"Lazaris AM, Kontopantelis E, Antonopoulos K, Mantas G, Kouvelos G, Moulakakis K, et al. Effect of diabetes mellitus on the clinical outcome of lower limb arterial bypass surgery: A propensity score analysis. Vascular. 2017;25(4):364\u201371. https:\/\/doi.org\/10.1177\/1708538116682911.","journal-title":"Vascular"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-026-07951-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-026-07951-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-026-07951-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T20:03:02Z","timestamp":1788811382000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-026-07951-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,7]]},"references-count":25,"alternative-id":["7951"],"URL":"https:\/\/doi.org\/10.1007\/s10557-026-07951-x","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,7]]},"assertion":[{"value":"2 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki, ICH-GCP guidelines, and Korean Good Clinical Practice regulations. The protocol was approved by the Ministry of Food and Drug Safety and the Institutional Review Board at each participating center, including Severance Hospital, Yonsei University Health System (IRB No. 2018-2740-001).","order":1,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from all individual participants prior to any study-specific procedures, in accordance with KGCP and the principles of the Declaration of Helsinki.","order":2,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors affirm that human research participants provided informed consent for publication of the data presented in this manuscript. No individually identifiable patient data are included in any figures or tables.","order":3,"name":"Ethics","label":"Consent to Publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was sponsored and funded by Korea United Pharmaceutical. Young-Guk Ko serves as the Principal Investigator and reports receiving lecture honoraria from Korea United Pharmaceutical related to the findings of this trial. The remaining authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}